Pembrolizumab + Sacituzumab Govitecan for Non-Small Cell Lung Cancer
This trial compares pembrolizumab alone with pembrolizumab plus a different drug to see how well they work in treating metastatic non-small cell lung cancer.
2 Primary · 16 Secondary · Reporting Duration: Up to approximately 48 months
2 Treatment Groups
Pembrolizumab + Sacituzumab Govitecan
1 of 2
1 of 2
614 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab + Sacituzumab Govitecan · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2023. "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05609968.
Frequently Asked Questions
What is the current size of the cohort participating in this trial?
"Accurate. Information posted to clinicaltrials.gov confirms that this medical trial is currently recruiting patients, having first been uploaded on February 10th 2023 and more recently edited January 13th 2023. Approximately 614 participants must be found from a single site for the project to move forward." - Anonymous Online Contributor
Has the combination of Pembrolizumab and Sacituzumab Govitecan been validated by the FDA?
"Pembrolizumab + Sacituzumab Govitecan is estimated to be of high safety, as evidenced by its 3 rating on our scale. The Phase 3 trial has generated data that both confirms efficacy and bolsters the drug's security profile." - Anonymous Online Contributor
Are there any ongoing enrolment opportunities in this experiment?
"Affirmative. According to the data hosted on clinicaltrials.gov, this medical test is presently searching for participants and was first posted in February 10th 2021 while most recently updated on January 13th 2021. The project demands 614 patients from one location." - Anonymous Online Contributor
What is the intended outcome of this experiment?
"The primary outcome for this clinical trial, which is expected to span up to 34 months, will be Overall Survival (OS). Secondary outcomes include Objective Response (OR) and Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30), as well as Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30." - Anonymous Online Contributor